Zacks Investment Research Lowers Kura Oncology (NASDAQ:KURA) to Hold

Share on StockTwits

Zacks Investment Research cut shares of Kura Oncology (NASDAQ:KURA) from a buy rating to a hold rating in a research report released on Wednesday morning, Zacks.com reports.

According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “

Several other research analysts have also weighed in on KURA. Wedbush assumed coverage on Pinterest in a research report on Monday, June 17th. They issued an outperform rating and a $33.00 price objective for the company. ValuEngine upgraded United Overseas Bank from a sell rating to a hold rating in a research note on Monday, June 17th. HC Wainwright set a $31.00 target price on Kura Oncology and gave the company a buy rating in a research note on Wednesday, May 8th. Citigroup set a $27.00 target price on PhaseBio Pharmaceuticals and gave the company a buy rating in a research note on Friday, May 24th. Finally, Oppenheimer set a $13.00 target price on Alpine Immune Sciences and gave the company a buy rating in a research note on Tuesday, March 19th. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. Kura Oncology presently has a consensus rating of Buy and a consensus price target of $28.00.

KURA stock opened at $20.15 on Wednesday. The stock has a 50-day simple moving average of $18.43. Kura Oncology has a 1-year low of $10.20 and a 1-year high of $22.00. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.80 and a current ratio of 13.80. The company has a market cap of $769.53 million, a price-to-earnings ratio of -11.72 and a beta of 2.51.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.37) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.45) by $0.08. On average, equities analysts forecast that Kura Oncology will post -1.71 earnings per share for the current year.

In other news, insider Antonio Gualberto sold 18,000 shares of the firm’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $21.11, for a total value of $379,980.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 15.30% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the business. Legal & General Group Plc boosted its stake in Kura Oncology by 21.7% during the 4th quarter. Legal & General Group Plc now owns 5,175 shares of the company’s stock valued at $73,000 after purchasing an additional 923 shares during the last quarter. CWM LLC acquired a new position in Kura Oncology during the 1st quarter valued at about $25,000. DekaBank Deutsche Girozentrale boosted its stake in Kura Oncology by 22.4% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 12,000 shares of the company’s stock valued at $235,000 after purchasing an additional 2,200 shares during the last quarter. Legacy Advisors LLC acquired a new position in Kura Oncology during the 1st quarter valued at about $65,000. Finally, Alps Advisors Inc. boosted its stake in Kura Oncology by 4.5% during the 1st quarter. Alps Advisors Inc. now owns 91,873 shares of the company’s stock valued at $1,524,000 after purchasing an additional 3,974 shares during the last quarter. Institutional investors and hedge funds own 83.93% of the company’s stock.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Read More: What Are Cryptocurrencies?

Get a free copy of the Zacks research report on Kura Oncology (KURA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.